Details of the Drug Combination

General Information of Drug Combination (ID: DCD3GLE)

Drug Combination Name

Picoplatin DFN-15

Indication

Disease Entry	Status	REF
Colon carcinoma	Investigative	[1]

Component Drugs

Picoplatin DM0PIY6

DFN-15 DM3BF9B

Small molecular drug

N.A.

High-throughput Screening Result

Testing Cell Line: KM12

Zero Interaction Potency (ZIP) Score: 1.12

Bliss Independence Score: 3.47

Loewe Additivity Score: 12.16

LHighest Single Agent (HSA) Score: 11.76

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Large cell lung carcinoma	DCTGZ41	NCI-H460	Investigative	[4]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976